Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026
- All agenda items approved by a large majority
- 2026 Annual General Meeting elects Jack Yefei Ling as new member of the Supervisory Board
Ladenburg, Germany, 23 June 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company's shareholders approved the management proposals with a large majority (between 98.67% and 98.72%) at today's ordinary virtual Annual General Meeting.
- All members of the Management Board and Supervisory Board formally approved for the 2024/2025 financial year
- Auditors for the 2025/2026 financial year appointed
- Remuneration report for the Management Board approved
- Election of Mr. Jack Yefei Ling as new member of the Supervisory Board
- Resolution on the amendment to the Articles of Association regarding the reduction in the size of the Supervisory Board from seven to five members
Attendance (incl. postal votes cast) at the 2026 Annual General Meeting corresponded to 80.55% of the current capital stock.
For more information on the Annual General Meeting, including the voting results, please visit: https://heidelberg-pharma.com/en/agm.
